FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2892831227> ?p ?o ?g. }

• W2892831227 endingPage "354" @default.
• W2892831227 startingPage "340" @default.
• W2892831227 abstract "Background There are scarce data in Scandinavia about treatment satisfaction among patients with psoriasis (PsO) and/or psoriatic arthritis (PsA). The number of patients receiving systemic treatment is unknown. Objective To describe patients’ experience of treatments for PsO/PsA in Sweden, Denmark and Norway, addressing communication with physicians, satisfaction with treatment and concerns regarding treatment options. Methods The NORdic PAtient survey of Psoriasis and Psoriatic arthritis (NORPAPP) asked 22 050 adults (randomly selected from the YouGov panels in Sweden, Denmark and Norway) whether they had PsO/PsA. A total of 1264 individuals who reported physician-diagnosed PsO/PsA were invited to participate in the full survey; 96.6% responded positively. Results Systemic treatment use was reported by 14.6% (biologic: 8.1%) of respondents with PsO only and by 58.5% (biologic: 31.8%) of respondents with PsA. Biologic treatments were more frequently reported by respondents considering their disease severe (26.8% vs 6.7% non-severe) and those who were members of patient organizations (40.7% vs 6.9% non-members). Discussing systemic treatments with their physician was reported significantly more frequently by respondents with PsA, those perceiving their disease as severe (although 35.2% had never discussed systemic treatment with their physician) and those reporting being a member of a patient organization (P < 0.05). Many respondents reported health risk concerns and dissatisfaction with their treatment. Of special interest was that respondents aged 45–75 years reported less experience with biologics (8.1%) than those aged 18–44 years (21.5%). The older respondents also reported more uncertainty regarding long-term health risks related to systemic treatments (most [66.7–72.9%] responded ‘do not know’ when asked about the risk of systemic options). Conclusion It appears likely that substantial numbers of Scandinavians suffering from severe PsO/PsA are not receiving optimal treatment from a patient perspective, particularly older patients. Also, one-third of respondents with severe symptoms had never discussed systemic treatment with a physician." @default.
• W2892831227 created "2018-10-05" @default.
• W2892831227 creator A5003685940 @default.
• W2892831227 creator A5009118689 @default.
• W2892831227 creator A5024722895 @default.
• W2892831227 creator A5035700990 @default.
• W2892831227 creator A5045620631 @default.
• W2892831227 creator A5072664936 @default.
• W2892831227 creator A5085525052 @default.
• W2892831227 date "2018-11-28" @default.
• W2892831227 modified "2023-10-14" @default.
• W2892831227 title "Treatment use and satisfaction among patients with psoriasis and psoriatic arthritis: results from the NORdic PAtient survey of Psoriasis and Psoriatic arthritis (NORPAPP)" @default.
• W2892831227 cites W1648776832 @default.
• W2892831227 cites W1895427692 @default.
• W2892831227 cites W1905701786 @default.
• W2892831227 cites W1922692046 @default.
• W2892831227 cites W1980883233 @default.
• W2892831227 cites W1997690403 @default.
• W2892831227 cites W2034350610 @default.
• W2892831227 cites W2058547807 @default.
• W2892831227 cites W2086465586 @default.
• W2892831227 cites W2097170399 @default.
• W2892831227 cites W2104595106 @default.
• W2892831227 cites W2119275077 @default.
• W2892831227 cites W2138319643 @default.
• W2892831227 cites W2139788459 @default.
• W2892831227 cites W2151444904 @default.
• W2892831227 cites W2152262899 @default.
• W2892831227 cites W2153141678 @default.
• W2892831227 cites W2156148414 @default.
• W2892831227 cites W2167606334 @default.
• W2892831227 cites W2223534783 @default.
• W2892831227 cites W2297053275 @default.
• W2892831227 cites W2327118542 @default.
• W2892831227 cites W2406709313 @default.
• W2892831227 cites W2541138259 @default.
• W2892831227 cites W2609891954 @default.
• W2892831227 cites W2751988834 @default.
• W2892831227 cites W2888446574 @default.
• W2892831227 doi "https://doi.org/10.1111/jdv.15252" @default.
• W2892831227 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6587823" @default.
• W2892831227 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30242921" @default.
• W2892831227 hasPublicationYear "2018" @default.
• W2892831227 type Work @default.
• W2892831227 sameAs 2892831227 @default.
• W2892831227 citedByCount "23" @default.
• W2892831227 countsByYear W28928312272019 @default.
• W2892831227 countsByYear W28928312272020 @default.
• W2892831227 countsByYear W28928312272021 @default.
• W2892831227 countsByYear W28928312272022 @default.
• W2892831227 countsByYear W28928312272023 @default.
• W2892831227 crossrefType "journal-article" @default.
• W2892831227 hasAuthorship W2892831227A5003685940 @default.
• W2892831227 hasAuthorship W2892831227A5009118689 @default.
• W2892831227 hasAuthorship W2892831227A5024722895 @default.
• W2892831227 hasAuthorship W2892831227A5035700990 @default.
• W2892831227 hasAuthorship W2892831227A5045620631 @default.
• W2892831227 hasAuthorship W2892831227A5072664936 @default.
• W2892831227 hasAuthorship W2892831227A5085525052 @default.
• W2892831227 hasBestOaLocation W28928312272 @default.
• W2892831227 hasConcept C126322002 @default.
• W2892831227 hasConcept C141071460 @default.
• W2892831227 hasConcept C16005928 @default.
• W2892831227 hasConcept C1862650 @default.
• W2892831227 hasConcept C2775944032 @default.
• W2892831227 hasConcept C2776260265 @default.
• W2892831227 hasConcept C2777077863 @default.
• W2892831227 hasConcept C2779134260 @default.
• W2892831227 hasConcept C2780564577 @default.
• W2892831227 hasConcept C512399662 @default.
• W2892831227 hasConcept C71924100 @default.
• W2892831227 hasConceptScore W2892831227C126322002 @default.
• W2892831227 hasConceptScore W2892831227C141071460 @default.
• W2892831227 hasConceptScore W2892831227C16005928 @default.
• W2892831227 hasConceptScore W2892831227C1862650 @default.
• W2892831227 hasConceptScore W2892831227C2775944032 @default.
• W2892831227 hasConceptScore W2892831227C2776260265 @default.
• W2892831227 hasConceptScore W2892831227C2777077863 @default.
• W2892831227 hasConceptScore W2892831227C2779134260 @default.
• W2892831227 hasConceptScore W2892831227C2780564577 @default.
• W2892831227 hasConceptScore W2892831227C512399662 @default.
• W2892831227 hasConceptScore W2892831227C71924100 @default.
• W2892831227 hasFunder F4320309086 @default.
• W2892831227 hasIssue "2" @default.
• W2892831227 hasLocation W28928312271 @default.
• W2892831227 hasLocation W28928312272 @default.
• W2892831227 hasLocation W28928312273 @default.
• W2892831227 hasLocation W28928312274 @default.
• W2892831227 hasLocation W28928312275 @default.
• W2892831227 hasLocation W28928312276 @default.
• W2892831227 hasLocation W28928312277 @default.
• W2892831227 hasLocation W28928312278 @default.
• W2892831227 hasOpenAccess W2892831227 @default.
• W2892831227 hasPrimaryLocation W28928312271 @default.
• W2892831227 hasRelatedWork W1566732118 @default.
• W2892831227 hasRelatedWork W1973094410 @default.
• W2892831227 hasRelatedWork W1998912255 @default.
• W2892831227 hasRelatedWork W2114372554 @default.

• next